Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Streamlined workflow for HPV test, 9/13

The FDA in June approved a workflow process for Roche Diagnostics’ Cobas HPV test that allows sample processing from the primary sample collection vial after it has been used for cytology (Pap) testing. The approval allows labs to load the same vial used for a ThinPrep Pap test directly onto Roche’s Cobas 4800 system for high-risk HPV and individual HPV 16 and 18 genotype testing. The new workflow option uses a special primary vial rack for the fully automated Cobas

Intelligent lab automation solution, 9/13

Roche’s Cobas 8100 automated workflow series is an advanced system designed to automate many routine tasks to help diagnostic laboratories increase efficiency, reduce expenses, and maximize patient safety. Through intelligent robotics, the Cobas 8100 series automatically prepares blood samples for immediate testing and post-analytical processing, providing high-speed processing of up to 1,100 samples per hour. The system offers dynamic and efficient sample transport options and great flexibility, allowing labs to automate routine and stat tests. Health care professionals benefit from

Vitamin D assay, 9/13

Tosoh Bioscience’s ST AIA-Pack 25-OH vitamin D assay is for use on most Tosoh AIA system analyzers. Vitamin D measurement is intended as an aid in the determination of vitamin D sufficiency. Using Tosoh’s unit-dose test-cup reagent technology, ST AIA-Pack 25-OH vitamin D has an assay time of about 40 minutes. Single, unitized test cups require no premixing, no premeasuring, and no onboard refrigeration. Dry-reagent format ensures 90-day calibration stability for minimal waste and cost-effective testing. Test cups are bar

Mobile cardiac diagnostic device, 9/13

Samsung Electronics presented details of the first peer-reviewed report of a pilot conducted with the National Health Service in Scotland, Borders General Hospital, the Scottish Ambulance Service, and the Scottish Centre for Telehealth and Telecare on the use of the company’s Labgeo IB10 portable blood analyzer to diagnose cardiac patients in transit to the hospital. Conducted in the sparsely populated Scottish Borders, the pilot sought to demonstrate the feasibility of diagnosing whether chest pain patients were suffering from a heart

Tuberculosis test, 9/13

Cepheid has received FDA market authorization for its Xpert MTB/RIF test, which provides results in about two hours. The review decision was based on the de novo 510(k) review process, which allows novel products without predicates to be downclassified and brought to market. Xpert MTB/RIF is for the rapid molecular detection of Mycobacterium tuberculosis complex (MTB-complex) DNA and, in specimens where MTB-complex DNA is detected, Xpert MTB/RIF also detects rifampin-resistant associated mutations of the rpoB gene. Designed for use on

HIV-1 test added to mPlus menu, 9/13

September 2013—Abbott has received FDA approval to expand the use of its RealTime HIV-1 assay to run on the company’s mPlus system. In April, Abbott introduced mPlus capability for its RealTime m2000 system to enhance the system’s flexibility and make molecular testing easier and more efficient for laboratories.

Troponin assay, 9/13

AACC 2013 Abbott announced results from a study evaluating its high sensitive troponin-I (hsTnI) assay. The study, conducted by researchers at Brigham and Women’s Hospital, demonstrated that Abbott’s Architect stat hsTnI test may help doctors predict which patients presenting with symptoms of a heart attack are at a higher risk for having a heart attack 30 days after presentation. Researchers at Brigham and Women’s evaluated the performance of Abbott’s Architect stat hsTnI assay with the performance of a fourth-generation troponin

Incubators, 9/13

Eppendorf North America offers a new generation of its ThermoMixer and ThermoStat incubators. The excellent mixing results of the ThermoMixer C, F1.5 and FP (two-in-one instruments for combined mixing and incubating) are due to the company’s two-dimensional mix-control technology, which ensures fast and efficient mixing in seconds. Through controlled circular movements, liquids in small volumes are thoroughly mixed, while anti-spill technology prevents lid wetting and cross-contamination. For dry incubation, the company’s ThermoMixer C and ThermoStat C operate together with SmartBlocks,

Extended mutation detection technology, 9/13

Seegene has launched its multiple mutation detection technology to accelerate the development of companion diagnostic tests. The technology transforms conventional real-time instruments into powerful systems to simultaneously detect multiple mutation targets in a single channel. Seegene has extended the capabilities of its real-time PCR technology to simultaneously detect more than 20 different mutations, including insertions, deletions, and point mutations, in a single tube and single reaction. The technology detects minority mutation or species when wild-type is in excess of 10,000-fold

Safety device for blood draws, 9/13

Greiner Bio-One’s Vacuette Tube-Touch passive safety device has a passive safety shield that activates upon tube insertion, reducing the risk of exposure to bloodborne pathogens from a needlestick. The product comes to the customer completely assembled with a needle, safety shield, and tube holder. Greiner Bio-One, 888-286-3883

MARKETPLACE

TRENDING